Abstract:Background: Mainstream application of cancer immunotherapy is hampered by the low response rate of most cancer patients. A novel immunotherapeutic target or a biomarker predicting response to immunotherapy needs to be developed. Guanylate-binding protein 1 (GBP1) is an interferon (IFN)-inducible guanosine triphosphatases (GTPases) involving inflammation and infection. However, the immunological effects of GBP1 in pan-cancer patients are still obscure. Methods: Using large-scale public data, we delineated the landscape of GBP1 across 33 cancer types. The correlation between GBP1 expression or mutation and immune cell infiltration was estimated by ESTIMATE, TIMER, xCell, and quanTIseq algorithms. GBP1-related genes and proteins were subjected to function enrichment analysis. Clustering analysis explored the relationship between GBP1 expression and anti-tumor immune phenotypes. We assessed the patient’s response to immunotherapy using the tumor immune dysfunction and exclusion (TIDE) score and immunophenoscore (IPS). Furthermore, we validated the predictive power of GBP1 expression in four independent immunotherapy cohorts. Results: GBP1 was differentially expressed in tumors and normal tissues in multiple cancer types. Distinct correlations existed between GBP1 expression and prognosis in cancer patients. GBP1 expression and mutation were positively associated with immune cell infiltration. Function enrichment analysis showed that GBP1-related genes were enriched in immune-related pathways. Positive correlations were also observed between GBP1 expression and the expression of immune checkpoints, as well as tumor mutation burden (TMB). Pan-cancer patients with higher GBP1 expression were more inclined to display “hot” anti-tumor immune phenotypes and had lower TIDE scores and higher immunophenoscore, suggesting that these patients had better responses to immunotherapy. Patients with higher GBP1 expression exhibited improved overall survival and clinical benefits in immunotherapy cohorts, including the Gide et al. cohort [area under the curve (AUC): 0.813], the IMvigor210 cohort (AUC: 0.607), the Lauss et al. cohort (AUC: 0.740), and the Kim et al. cohort (AUC: 0.793). Conclusion: This study provides comprehensive insights into the role of GBP1 in a pan-cancer manner. We identify GBP1 expression as a predictive biomarker for immunotherapy, potentially enabling more precise and personalized immunotherapeutic strategies in the future.

Function and mechanism of GBP1 in the development and progression of cervical cancer

GBP1&nbsp;Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Gastric Cancer

Overexpression of GBP1 Predicts Poor Prognosis and Promotes Tumor Growth in Human Glioblastoma Multiforme.

Effects of GBP1 gene silencing on proliferation and migration of cervical cancer CaSki cell line

The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer bioinformatics

Integrative analysis of the immunological significances of guanylate binding protein family genes in microsatellite stability colorectal cancer

Comprehensive Analysis of the Expression and Prognosis for GBPs in Head and neck squamous cell carcinoma

Regulation of BMP2K in AP2M1-mediated EGFR Internalization During the Development of Gallbladder Cancer

Guanylate-Binding Protein 1: An Emerging Target in Inflammation and Cancer

The Effect of HMGB1 on the Clinicopathological and Prognostic Features of Cervical Cancer.

Guanylate‐binding Proteins Signature Predicts Favorable Prognosis, Immune‐hot Microenvironment, and Immunotherapy Response in Hepatocellular Carcinoma

GBP5 Drives Malignancy of Glioblastoma Via the Src/ERK1/2/MMP3 Pathway.

GBP2 as a potential prognostic predictor with immune-related characteristics in glioma

GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer

Correlation between the risk of lymph node metastasis and the expression of GBP1 in breast cancer patients

Guanylate-binding Protein 2 Expression Is Associated With Poor Survival and Malignancy in Clear-cell Renal Cell Carcinoma

Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis

GBP1 promotes cutaneous squamous cell carcinoma proliferation and invasion through activation of STAT3 by SP1

Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target

Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro

GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway